These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

562 related items for PubMed ID: 27151773

  • 1. Tolerability of Therapies Recommended for the Treatment of Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer.
    Ohno S.
    Clin Breast Cancer; 2016 Aug; 16(4):238-46. PubMed ID: 27151773
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of fulvestrant in postmenopausal patients with hormone receptor-positive advanced breast cancer: a systematic literature review and meta-analysis.
    Wang J, Xu B, Wang W, Zhai X, Chen X.
    Breast Cancer Res Treat; 2018 Oct; 171(3):535-544. PubMed ID: 29974356
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.
    Gradishar WJ.
    Oncology; 2005 Oct; 69(1):1-9. PubMed ID: 16088229
    [Abstract] [Full Text] [Related]

  • 8. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
    Mouridsen HT.
    Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085
    [Abstract] [Full Text] [Related]

  • 9. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.
    Howell SJ, Johnston SR, Howell A.
    Best Pract Res Clin Endocrinol Metab; 2004 Mar; 18(1):47-66. PubMed ID: 14687597
    [Abstract] [Full Text] [Related]

  • 10. [Adjuvant antihormonal therapy for postmenopausal women with primary operable breast cancer].
    Tuxen MK, Nielsen DL, Lindberg H, Kamby C.
    Ugeskr Laeger; 2007 Jan 22; 169(4):297-9. PubMed ID: 17274922
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M.
    Clin Ther; 2007 Aug 22; 29(8):1535-47. PubMed ID: 17919537
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Hormonal therapy for advanced breast cancer.
    Rugo HS.
    Hematol Oncol Clin North Am; 2007 Apr 22; 21(2):273-91. PubMed ID: 17512449
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Advances in adjuvant hormonal therapy for postmenopausal women.
    Strasser-Weippl K, Goss PE.
    J Clin Oncol; 2005 Mar 10; 23(8):1751-9. PubMed ID: 15755983
    [No Abstract] [Full Text] [Related]

  • 18. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.
    Robertson JFR, Bondarenko IM, Trishkina E, Dvorkin M, Panasci L, Manikhas A, Shparyk Y, Cardona-Huerta S, Cheung KL, Philco-Salas MJ, Ruiz-Borrego M, Shao Z, Noguchi S, Rowbottom J, Stuart M, Grinsted LM, Fazal M, Ellis MJ.
    Lancet; 2016 Dec 17; 388(10063):2997-3005. PubMed ID: 27908454
    [Abstract] [Full Text] [Related]

  • 19. Endocrine therapy for advanced/metastatic breast cancer.
    Schiavon G, Smith IE.
    Hematol Oncol Clin North Am; 2013 Aug 17; 27(4):715-36, viii. PubMed ID: 23915741
    [Abstract] [Full Text] [Related]

  • 20. Endocrine therapy for the treatment of postmenopausal women with breast cancer.
    Harichand-Herdt S, Zelnak A, O'Regan R.
    Expert Rev Anticancer Ther; 2009 Feb 17; 9(2):187-98. PubMed ID: 19192957
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.